Symbol Lookup

Monday May 25, 2015 11:20 PM ET. Data delayed 15 minutes.
6.10
-0.10 (-1.61%)
Bid/Lots
6.11/11
Ask/Lots
6.14/2
Open/Prev Close
6.20/6.20
Day Range
6.00-6.20
52-Week Range
4.40-15.24
Vol/Avg Daily Vol
73.9K/259.5K
  • TSX Comp
  • TSX Venture
  • DJIA
  • S&P 500
  • NASDAQ
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

0 New Today
Cytosorbents Climbs 1% on Exclusive Deal with AlphaMedix to Distribute CytoSorb in Israel
10:20AM ET on Tuesday May 19, 2015 by Midnight Trader
10:20 AM EDT, 05/19/2015 (MT Newswires) -- Shares of Cytosorbents Corp. (CTSO) gained Tuesday morning after the New Jersey-based blood purification therapy company said it has sealed an exclusive agreement with AlphaMedix to distribute the CytoSo...
CytoSorbents and Alphamedix Team To Introduce CytoSorb(R) to Israel
8:31AM ET on Tuesday May 19, 2015 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb(R) extracorporeal cytokine adsorber to purify blood and control severe inflammation, today announced that it has established an exclus...

Analyst Actions: Cytosorbents Price Target Cut To $21 At MLV & Co., Reiterated Buy
12:02PM ET on Tuesday May 12, 2015 by Midnight Trader
12:02 PM EDT, 05/12/2015 (MT Newswires) -- Cytosorbents (CTSO) saw its price target lowered to $21 from $28 by MLV & Co. while the firm retained its buy rating. Price: 6.80, Change: -0.31, Percent Change: -4.36 ...
CytoSorbents Reports 24% Year-over-Year Increase in CytoSorb(R) Sales in First Quarter 2015
8:00AM ET on Monday May 11, 2015 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy company commercializing its CytoSorb(R) cytokine adsorber to treat critically-ill and cardiac surgery patients in multiple countries worldwide, reported financial and operat...

CytoSorbents to Report Q1 2015 Operating and Financial Results
7:00AM ET on Monday May 04, 2015 by PR Newswire

CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb(R) extracorporeal cytokine adsorber to treat critically-ill and cardiac surgery patients in multiple countries worldwide, will report...

Company Information

CytoSorbents Corporation is a development stage critical care focused immunotherapy company using blood purification to modulate inflammation to preventing or treating multiple organ failure in life-threatening illnesses. The technology is based upon biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances, such as drugs, dangerous chemicals, toxins, cytokines, free hemoglobin, and antibodies, from blood and other bodily fluids. In addition to CytoSorb, the Company is developing other products utilizing its adsorbent polymer technology that have not received regulatory approval including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

CONTACT INFORMATION

Headquarters7 Deerpark Dr Ste K
MONMOUTH JUNCTION, NJ, United States 08852-1921
Phone973-329-8885
Fax732-329-8650

EXECUTIVE OFFICERS

Chairman of the BoardAl Kraus
President, Chief Executive Officer, DirectorPhillip Chan
Chief Financial OfficerKathleen Bloch
Chief Operating OfficerVincent Capponi
Chief Medical OfficerRobert Bartlett

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

  •  
  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • S&P Capital IQ Stock Report

    S&P Capital IQ's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap$151.1MBeta-0.07
Revenue (TTM)$3.8MEPS$-1.15
Shares Out.24.8MBook Value$0.17
Dividend Yield0.00%P/E--
Annual Dividend Rate0.00 USDPrice/Sales (TTM)39.9
Ex-Div Date1/1/01P/Cash Flow (TTM)--
Pay Date1/1/01Operating Margin-233.53%

*GAAP = prior to non-GAAP analyst adjusted earnings.

(Non-GAAP)*

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample